Immune killer cells treatment for previously treated stage IV NSCLC patients

• Published in: Scientific reports 2024-08, Vol.14 (1), p.19374-10
• Main Authors: Tseng, Yen-Han, Ho, Ching-Liang, Chian, Chih-Feng, Chiang, Chi-Lu, Chao, Heng-Sheng, Tsai, Chen-Liang, Perng, Wann-Cherng, Hsiao, Chin-Fu, Chuang, Mei-Hsing, Ko, Kai-Hsiung, Cheng, Yun-Ching, Chen, Shin-Jung, Wang, Chia-Jen, Chen, Yuh-Min
• Format: Article
• Language: English
• Subjects: 631/250; 631/67; 692/308; Adult; Aged; Carcinoma, Non-Small-Cell Lung - immunology; Carcinoma, Non-Small-Cell Lung - mortality; Carcinoma, Non-Small-Cell Lung - pathology; Carcinoma, Non-Small-Cell Lung - therapy; Cell immunotherapy; Chemotherapy; Female; Humanities and Social Sciences; Humans; Immune killer cells; Immunotherapy; Immunotherapy, Adoptive - adverse effects; Immunotherapy, Adoptive - methods; Killer cells; Lung cancer; Lung Neoplasms - immunology; Lung Neoplasms - mortality; Lung Neoplasms - pathology; Lung Neoplasms - therapy; Male; Middle Aged; multidisciplinary; NCT; NCT03499834; Neoplasm Staging; Non-small cell lung cancer; Non-small cell lung carcinoma; Overall survival; Progression-Free Survival; Quality of Life; Safety; Science; Science (multidisciplinary); Small cell lung carcinoma; Survival; Treatment Outcome
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-024-69587-x

The 5-year survival is poor for stage IV non-small cell lung cancer (NSCLC). Recently, cell immunotherapy has emerged as a new treatment strategy. This study aimed to evaluate the efficacy and safety of Immune killer cells (IKC) in patients with stage IV NSCLC after the failure of prior chemotherapy. This study enrolled 26 patients with stage IV NSCLC who failed at least two lines of chemotherapy with or without targeted therapy. The IKC was given alone weekly for 24 weeks. The primary endpoint was progression-free survival (PFS). Secondary outcomes included overall survival (OS), pain intensity, quality of life (QOL), and safety. The median PFS for the intent-to-treat (ITT) population (i.e., all enrolled patients) was 3.8 month. In the per-protocol (PP) population (i.e., patients receiving > 12 IKC infusions), the median PFS was 5.6 months. Moreover, the ITT population showed a 1-year survival rate of 60.0%, while that for the PP population was 85.7%. Only 7 out of 200 AEs (3.5%) were related to the IKC infusion, and they were all rated as grade 1 in severity. The IKC infusion was well tolerated. This novel immunotherapy prolonged the PFS and improved the survival compared with historical data. It might be a potential treatment strategy for stage IV NSCLC patient who failed prior chemotherapy. ClinicalTrials.gov identifier: NCT03499834.